Australia's largest stock trading and investment forum Australia's #1 stock forum

CHM

Click for more information

0.00%

1.4¢ chimeric therapeutics limited

Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation, page-16

First 16 Last

Share
Profile

Follow
NZ Trader

12,293 Posts.

6309

22/05/24

10:12

Post #: 73948782
Share

Originally posted by DrillDown2014: ↑

I raised this issue at yesterday's investor lunch. Need some positive promotion badly in between updates that are dictated mostly by clinical progress.

Seems management is letting it drift. They have said previously that there is a gap in our valuation and the value of the underlying assets and I 100% agree. What is management doing to better inform the market in order to close this preceived gap? This gap needs to be closed before the next cap raise and CHM cannot leave it to market updates like CDH17 first dosing etc as we know there is potenetial here but the lead time is an issue with the pending funding requirements of the business in the meantime.

CHM needs to spruik the value of the tech and get some positive retail momentum and uplift in the SP before they go to the Soph's and Instituitions for funding.

I will post some feedback from yesterday when I get some time.

Expand

Thanks Drilldown , we all would appreciate any insight you can deliver,,, NZT

CHM Price at posting: 2.3¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ASM

ASM to push Dubbo REE play towards economical production with A$5M Federal govt grant

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

A1G

African Gold finds significant 5.5g/t intercept over 65m in Cote d’Ivoire

Wealth Within: the latest stock tips from Dale Gillham

There are more pages in this discussion • 3 more messages in this thread...

First 16 Last

Add CHM (ASX) to my watchlist

SPONSORED BY